Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNION PRECISION-I: Neoadjuvant Fruquintinib + Adebrelimab + CAPOX in LARC
NCT06234007Phase 2Recruiting
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and adebrelimab in rectal cancer. Primary endpoint: Pathology Complete Response at 6 months. Started Dec 2023; status: recruiting.
02
Drugs
fruquintinibadebrelimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06234007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234007.